Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bupranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.58 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.55 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupranolol SCHEMBL348362 | 1.00 | L3MBTL1 (0.65) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Bupranolol SCHEMBL6508337 | 0.99 | L3MBTL1 (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Bupranolol SCHEMBL2497819 | 0.99 | L3MBTL1 (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Bupranolol SCHEMBL123717 | 0.99 | L3MBTL1 (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Bupranolol SCHEMBL29518497 | 0.99 | L3MBTL1 (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Bupranolol SCHEMBL34061 | 0.99 | L3MBTL1 (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| SCHEMBL348361 | 0.91 | L3MBTL1 (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Bupranolol SCHEMBL8908385 | 0.89 | L3MBTL1 (0.53) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Cloranolol SCHEMBL1230788 | 0.88 | KMT2A (0.63) | L3MBTL1KMT2AMEN1HTTMAPT | |
| Cloranolol SCHEMBL1230787 | 0.88 | KMT2A (0.63) | L3MBTL1KMT2AMEN1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768514-A1 | LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION | Mercator Medsystems, Inc. (US) | 2014-08-27 | — | — | EP | claimed |
| US-20130252932-A1 | LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION | MERCATOR MEDSYSTEMS, INC. (US) | 2013-09-26 | — | — | US | claimed |
| WO-2013059735-A1 | LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION | MERCATOR MEDSYSTEMS, INC. (US) | 2013-04-25 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| JP-63104913-A | — | — | None | — | — | JP | disclosed |
| JP-52154528-A | — | — | None | — | — | JP | disclosed |
| US-20260144747-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4606435-A2 | PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE BASIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4316598-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY SOLUBLE BASIC AGENT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-4428883-A | NASAL OINTMENTS OR GELS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-01-31 | — | — | US | disclosed |
| EP-0073819-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1983-03-16 | — | — | EP | disclosed |
| WO-1982003009-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | UNIV KENTUCKY RES FOUND (US) | 1982-09-16 | — | — | WO | disclosed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | disclosed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | disclosed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| JP-S52154528-A | REMEDY FOR GLAUCOMA | KAKEN PHARMACEUT CO LTD | 1977-12-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | GLA 2750/4885ACHE 1719/4885ADRB2 2077/4885 |
| US-20260144747-A1 | SYRUP PREPARATION | ALK, IRAK1, IRAK3 | GLA 4454/4885ACHE 3413/4885ADRB2 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.